Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015, Article ID 137682, 3 pages
http://dx.doi.org/10.1155/2015/137682
Case Report

Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse

Department of Hematology, School of Medicine, Hacettepe University, 0100 Ankara, Turkey

Received 5 July 2015; Accepted 10 September 2015

Academic Editor: Jeffrey M. Weinberg

Copyright © 2015 Umit Yavuz Malkan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. Morton, S. S. Wang, S. S. Devesa, P. Hartge, D. D. Weisenburger, and M. S. Linet, “Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001,” Blood, vol. 107, no. 1, pp. 265–276, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-F. Larouche, F. Berger, C. Chassagne-Clément et al., “Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 2094–2100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Maurer, H. Ghesquières, J.-P. Jais et al., “Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1066–1073, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Weeks, B. Y. Yeap, G. P. Canellos, and M. A. Shipp, “Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission,” Journal of Clinical Oncology, vol. 9, no. 7, pp. 1196–1203, 1991. View at Google Scholar · View at Scopus
  5. M. Liedtke, P. A. Hamlin, C. H. Moskowitz, and A. D. Zelenetz, “Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population,” Annals of Oncology, vol. 17, no. 6, pp. 909–913, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. T. El-Galaly, K. J. Mylam, M. Bøgsted et al., “Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma,” American Journal of Hematology, vol. 89, no. 6, pp. 575–580, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Santucci and N. Pimpinelli, “Primary cutaneous B-cell lymphomas. Current concepts. I,” Haematologica, vol. 89, no. 11, pp. 1360–1371, 2004. View at Google Scholar · View at Scopus
  8. H. Kerl, R. Fink-Puches, and L. Cerroni, “Diagnostic criteria of primary cutaneous B-cell lymphomas and pseudolymphomas,” The Keio Journal of Medicine, vol. 50, no. 4, pp. 269–273, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Thomas, R. Dobson, and R. Mennel, “Primary cutaneous large B-cell lymphoma, leg type,” Proceedings of the Baylor University Medical Center, vol. 24, pp. 350–353, 2011. View at Google Scholar
  10. Y. Amo, R. Tanei, K. Yonemoto, K. Katsuoka, and M. Mori, “Diffuse large B-cell lymphoma associated with skin, muscle and cranial nerve involvement,” European Journal of Dermatology, vol. 10, no. 4, pp. 306–308, 2000. View at Google Scholar · View at Scopus
  11. N. Shamsudin and C. C. Chang, “Diffuse large B-cell lymphoma presenting with extensive cutaneous infiltration,” Singapore Medical Journal, vol. 53, no. 9, pp. e198–e200, 2012. View at Google Scholar · View at Scopus
  12. C. Gisselbrecht, B. Glass, N. Mounier et al., “Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4184–4190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. R. J. Singer and A. H. Goldstone, “Clinical studies of ABMT in non-Hodgkin's lymphoma,” Clinics in Haematology, vol. 15, no. 1, pp. 105–150, 1986. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Cortelazzo, A. Rambaldi, A. Rossi et al., “Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 114, no. 2, pp. 333–341, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Iguchi, K. Miyazawa, S. Okabe et al., “Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy,” Rinshō Ketsueki, vol. 45, no. 10, pp. 1129–1134, 2004. View at Google Scholar · View at Scopus
  16. W. T. Massengale, E. McBurney, and J. Gurtler, “CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy,” Journal of the American Academy of Dermatology, vol. 46, no. 3, pp. 441–443, 2002. View at Publisher · View at Google Scholar · View at Scopus